Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Akkermansia muciniphila EB-AMDK19
- Development stage
- Unknown
- Lead developer
- Enterobiome
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Akkermansia muciniphila EB-AMDK19** is a specific clade I (AmI) strain of the mucin-degrading gut bacterium Akkermansia muciniphila, developed and manufactured in a heat-killed (pasteurized) formulation for use as a next-generation probiotic. This strain has been studied for alleviating subacute respiratory symptoms, reducing breathlessness and cough in humans, and for modulating allergic airway inflammation, metabolic parameters, and obesity-related conditions in preclinical models. The mechanism of action appears to involve modulation of the gut–lung axis and suppression of Th2-mediated immune responses, including decreased IL-4 and IL-13 cytokine production, increased short-chain fatty acid concentrations, improved intestinal barrier function, and effects on inflammatory and metabolic parameters. EB-AMDK19 has demonstrated a favorable safety profile with no severe adverse events in clinical studies[1][2][3][4][5][9].
- Brand names
- ETB-F01ETB-F-01ETB-F 01
- Other names
- Akkermansia muciniphila strain EB-AMDK19heat-killed Akkermansia muciniphila EB-AMDK19sterilized Akkermansia muciniphila EB-AMDK19
02
Targets
AHR (Aryl hydrocarbon receptor)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Akkermansia muciniphila EB-AMDK19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akkermansia muciniphila EB-AMDK19.